Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arvinas Inc (ARVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11304
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s protein degradation technology platforms include proteolysis-targeting chimera and hydrophobic tagging which induce the loss of intracellular proteins. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations. It also develops degraders for targets in cancer, including androgen receptor, estrogen receptor and BET proteins. Arnivas is headquartered in New Haven, Connecticut, the US.

Arvinas Inc (ARVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Partnerships 16
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Licensing Agreements 17
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Amends Licensing Agreement with Yale University 20
Equity Offering 21
Arvinas Prices IPO of Shares for USD120 Million 21
Arvinas Inc – Key Competitors 23
Arvinas Inc – Key Employees 24
Arvinas Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Sep 20, 2017: Arvinas Appoints Dr. John Houston as President and Chief Executive Officer 26
Jan 05, 2017: Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer 27
Product News 28
12/20/2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program 28
Clinical Trials 29
Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium 29
Nov 02, 2017: Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program 30
Feb 17, 2017: Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Arvinas Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Amends Licensing Agreement with Yale University 20
Arvinas Prices IPO of Shares for USD120 Million 21
Arvinas Inc, Key Competitors 23
Arvinas Inc, Key Employees 24

List of Figures
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • WestRock Co:戦略・SWOT・企業財務分析
    WestRock Co - Strategy, SWOT and Corporate Finance Report Summary WestRock Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nostra Terra Oil and Gas Company plc (NTOG):企業の財務・戦略的SWOT分析
    Summary Nostra Terra Oil and Gas Company Plc (NTOG) is an oil and gas company. The company explores, produces, and develops oil and gas properties across the US. It holds interest in operating and non-operating working interests in its projects located in New Mexico, Permian Basin located in West Te …
  • NeuroVive Pharmaceutical AB (NVP):企業の財務・戦略的SWOT分析
    Summary NeuroVive Pharmaceutical AB (NeuroVive), formerly NeuroPharma i Sverige AB focuses on the research and development of mitochondrial therapies. The company’s programs include NeuroSTAT, a clinical phase II drug candidate for the prevention of traumatic brain injury; and phase I KL1333, a nove …
  • Nippon Flour Mills Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Black Hills Corporation (BKH):電力:M&Aディール及び事業提携情報
    Summary Black Hills Corporation (BHC) is a vertically-integrated energy company which offers electricity and natural gas. The company produces, transmits, and distributes electricity; and sells natural gas on retail and wholesale basis. It generates electricity from natural gas, coal, diesel oil, an …
  • Arcus Biosciences Inc (RCUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Arcus Biosciences Inc (Arcus Biosciences) is a clinical stage bio-pharmaceutical company. The company develops and commercializes cancer immunotherapies. Its product pipeline includes AB928, which is in phase 1/1b trial; AB122 is being developed for cancer patients, is in Phase 1 trial; AB15 …
  • Bracco Imaging SpA-医療機器分野:企業M&A・提携分析
    Summary Bracco Imaging SpA (Bracco), a subsidiary of Bracco SpA is a provider of diagnostic imaging solutions. The company offers diagnostic imaging, bracco pharma and health services. It offers solutions which include X-Ray, CT colonography, magnetic resonance imaging, diagnostic radiology, endosco …
  • Eagle Energy Inc (EGL):石油・ガス:M&Aディール及び事業提携情報
    Summary Eagle Energy Inc (Eagle) is an oil and gas company that acquires for, develops and produces oil and gas reserves through its subsidiaries. It focuses on the acquisition and exploitation of conventional long-life hydrocarbon reserves in on-shore production basins in North America. It acquires …
  • PEN, Inc. (PENC):企業の財務・戦略的SWOT分析
    PEN, Inc. (PENC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ramky Infrastructure Limited:企業の戦略・SWOT・財務情報
    Ramky Infrastructure Limited - Strategy, SWOT and Corporate Finance Report Summary Ramky Infrastructure Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …
  • Orkuveita Reykjavikur-エネルギー分野:企業M&A・提携分析
    Summary Orkuveita Reykjavikur (Orkuveita) is a public utility company that provides electricity and water. The company generates and supplies electricity. It harnesses hot water from geothermal fields and supplies it for heating applications. The company also supplies cold water from its groundwater …
  • University of Toronto-製薬・医療分野:企業M&A・提携分析
    Summary University of Toronto (UT) is an educational and research service provider that offers undergraduate and postgraduate courses in various fields. The university offers courses in various fields such as applied science and engineering, architecture, landscape, design, arts and science, continu …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Optum Inc-医療機器分野:企業M&A・提携分析
    Summary Optum Inc (Optum), a subsidiary of UnitedHealth Group Inc is a healthcare service provider that offers health IT, pharmacy care services, population health management, data and analytics, financial services, health care delivery, revenue cycle management, and health plan operations. The comp …
  • Societe Generale S.A.:企業のM&A・事業提携・投資動向
    Societe Generale S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Societe Generale S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • gel-e Inc:医療機器:M&Aディール及び事業提携情報
    Summary gel-e Inc (gel-e), formerly Remedium Technologies Inc, is a medical device company that provides products for the treatment of acute wounds. The company provides spray foams, bandages, gels, films, and band-aids. It provides proprietary technology platform that helps develop wound treatment …
  • Ameritas Mutual Holding Company:企業の戦略的SWOT分析
    Ameritas Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Women’s Choice Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Women's Choice Pharmaceuticals LLC (WCP) is a pharmaceutical company that provides branded prescription products for women’s health care and urology markets. The company’s products include fem pH, a therapeutic vaginal jelly that is used to promote and maintain vaginal acidity caused by diab …
  • Ossur hf (OSSR)-医療機器分野:企業M&A・提携分析
    Summary Ossur hf. (Ossur) is an orthopedic devices company. It develops, manufactures and sells prosthetics, and bracing and support products. The company’s key areas of expertise include silicone, carbon composites, mechatronics and textiles. Ossur offers ankle and foot supports, knee braces, neck …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆